The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience.

This study investigates the outcomes of patients with peripheral T-cell lymphoma (PTCL) treated with a doxorubicin-based regimen (CHOP) and a pirarubicin-based regimen (THP-COP). Newly diagnosed patients with PTCL between 2001 and 2021 were classified by initial treatment, either CHOP or THP-COP regimen. The treatment response, event-free survival (EFS), and overall survival (OS) were assessed. Overall, 65 patients were analyzed, with 41 classified into the CHOP group and 24 into the THP-COP group. Dose-intensified regimen was applied in 22 patients (53.7%) in the CHOP group and 16 (66.7%) in the THP-COP group. When stratified by treatment, the complete response (CR) rates in the CHOP group and the THP-COP group were 66% and 46% (P = 0.273), the 3-year EFS rates were 52.1% and 29.2% (P = 0.0492), and the 3-year OS rates were 72.7% and 48.6% (P = 0.0718), respectively. When stratified by treatment intensity, the CR rates in the dose-intensified group and the conventional dose group were 65% and 50% (P = 0.230), the 3-year EFS rates were 45.9% and 39.6% (P = 0.995), and the 3-year OS rates were 61.1% and 66.4% (P = 0.267), respectively. This study revealed no significant advantage of the THP-COP regimen over the CHOP regimen regarding treatment outcomes for newly diagnosed PTCLs.